Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;113(5):477-84.
doi: 10.1002/jso.24189. Epub 2016 Feb 2.

Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy

Nancy E Kemeny  1 , Joanne F Chou  2 , Taryn M Boucher  1 , Marinela Capanu  2 , Ronald P DeMatteo  3 , William R Jarnagin  3 , Peter J Allen  3 , Yuman C Fong  3   4 , Andrea Cercek  1 , Michael I D'Angelica  3
Affiliations

Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy

Nancy E Kemeny et al. J Surg Oncol. 2016 Apr.

Abstract

Background and objectives: Patients who undergo liver resection for metastatic colorectal cancer (mCRC) have reported 5-year survivals ranging from 25% to 50%. The current study updated long-term survival for patients with resected liver metastases treated with adjuvant hepatic arterial infusion (HAI) and systemic (SYS) chemotherapy.

Methods: Updated survival and recurrence free survival for patients treated on four consecutive adjuvant protocols with HAI and SYS from 1991 to 2009. Patients were divided into two groups: those treated on protocols before 2003 and after 2003. Median follow-up for all patients was 11 years.

Results: All 287 patients enrolled in four prospective protocols after liver resection are included. Patients treated before 2003 had a median follow-up of 15 years, 5 and 10-year survivals of 56% [95%CI: 49-64%] and 40% [95%CI: 32-47%], respectively, and median survival of 71 months. Patients treated after 2003 had a median follow-up of 9 years, 5 and 10-year survivals of 78% [95%CI: 70-84%] and 61% [95%CI: 51-70%], respectively, and median survival has not been reached.

Conclusions: Survival is improving for patients with mCRC who undergo liver resection. These data support the durability of long-term survival in patients who undergo resection followed by adjuvant HAI and SYS therapy. J. Surg. Oncol. 2016;113:477-484. © 2016 Wiley Periodicals, Inc.

Keywords: adjuvant therapy; colorectal cancer; hepatic arterial infusion; liver metastases; survival.

PubMed Disclaimer

Conflict of interest statement

The authors disclose no conflict of interest

Figures

Figure 1
Figure 1. Overall Survival According to Treatment Period
Figure 2
Figure 2. Recurrence Free Survival According to Treatment Period
Figure 3
Figure 3. Hepatic Recurrence Free Survival According to Treatment Period
Figure 4
Figure 4. Overall Survival According to KRAS Status
Figure 5
Figure 5. Recurrence Free Survival According to KRAS Status
See this image and copyright information in PMC

References

    1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:4677–3683. - PMC - PubMed
    1. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–321. - PMC - PubMed
    1. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–4580. - PubMed
    1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914. - PubMed
    1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947. - PubMed

MeSH terms